http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006145071-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10344 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8613 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate | 2005-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006145071-A |
| titleOfInvention | Chimeric adenoviruses for use in the treatment of malignant neoplasms |
| abstract | 1. Recombinant chimeric adenovirus, or a variant or derivative thereof, having a genome containing an E2B region, wherein said E2B region contains a nucleotide sequence derived from the first adenovirus serotype and a nucleotide sequence derived from the second adenovirus serotype; where the first and the second serotypes are each selected from subgroups of adenoviruses B, C, D, E, or F and differ from each other; and wherein said chimeric adenovirus is oncolytic and exhibits an increased therapeutic index in the tumor cell. The adenovirus according to claim 1, which further comprises sections encoding fibrillar, hexon and penton proteins, where the nucleic acid encoding the fibrillar, hexon and penton proteins of the specified adenovirus is obtained from the same adenovirus serotype. The adenovirus according to claim 1, which further comprises a modified portion of E3.4. Adenovirus according to claim 1, which further comprises a modified portion of E4.5. The adenovirus according to claim 1, wherein said tumor cell is a tumor cell of the colon, breast, pancreas, lung, prostate, ovary or hematopoietic cell. The adenovirus according to claim 5, wherein said tumor cell is a colon tumor cell. The adenovirus according to claim 1, wherein the nucleotide sequence of the E2B region of said adenovirus contains SEQ ID NO: 3 or a part thereof. The adenovirus according to claim 1, in which the nucleotide sequence of the specified adenovirus contains SEQ ID NO: 1.9. Recombinant chimeric adenovirus, or its � |
| priorityDate | 2004-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 339.